Skip to main content

Pathogenetix Raises $1.5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pathogenetix, formerly called US Genomics, has raised about $1.5 million, it disclosed in a document filed with the US Securities Exchange Commission.

In an amended Form D, the Woburn, Mass.-based firm targets about $1.8 million in equity in the round. The target and amount raised to date are up from the $1.3 million target and amount raised that Pathogenetix had cited in an SEC filing last month. Pathogenetix also said in November that it sold $900,000 in debt instruments.

The company did not identify investors on the $1.8 million round but related persons listed include Augustine Lawlor, a managing partner at HealthCare Ventures; Steve Gullans, a managing director at Excel Venture Management; and Enrico Petrillo, also a managing director at Excel Venture Management. The three are also directors of Pathogenetix.

The company did not say how the funds will be used but said it is not in connection with a business combination, such as a merger, acquisition, or exchange offer.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.